SCHEMBL2291382

SCHEMBL2291382

O=Cc1cnc(-c2cccc(I)c2)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.44
METAP2 P50579 1/20 0.37
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2E1 P05181 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2B6 P20813 1/20 0.36
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
CASP1 P29466 1/20 0.34
FAAH O00519 1/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29183439 0.83 PSMB8 (0.46) HSD17B1HSD17B2CYP2C9CYP2C19CYP2E1
SCHEMBL30751029 0.81 NPC1 (0.49) METAP2CYP2C9CYP2C19TSHRKDM4E
SCHEMBL29183392 0.81 NPC1 (0.49) METAP2CYP2C9CYP2C19TSHRKDM4E
SCHEMBL7450038 0.80 ALOX15 (0.53) CYP2C9CYP2C19CYP2E1CYP3A4CYP2D6
SCHEMBL30751038 0.78 NOTUM (0.51) KDM4EALDH1A1TDP1L3MBTL1MAPT
SCHEMBL29183398 0.78 NOTUM (0.51) KDM4EALDH1A1TDP1L3MBTL1MAPT
SCHEMBL9259362 0.77 ALOX15 (0.55) CYP2C9CYP2C19CYP2E1CYP3A4CYP2D6
SCHEMBL2288784 0.76 APP (0.50) APPMETAP2HSD17B1HSD17B2ALOX15
SCHEMBL27790043 0.74 CYP3A4 (0.59) CYP2C9CYP2C19CYP2E1CYP3A4CYP2D6
SCHEMBL14324716 0.72 ALDH1A1 (0.60) CYP2C9CYP2C19CYP2E1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2163554-B1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2012-08-01 EP disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed
EP-2163554-A1 PYRIMIDODIAZEPINONE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2010-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KCNJ1, KCNJ11, ADRA1D APP 2686/4885METAP2 3328/4885HSD17B1 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.